HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BAO PHARMA-B

16.140

+0.3202.02%

Volume:460.60K

Turnover:7.45M

Market Cap:5.23B

PE:-10.18

High:16.490

Open:15.850

Low:15.380

Close:15.820

52wk High:206.000

52wk Low:15.300

Shares:324.00M

HK Float Shares:153.00M

Volume Ratio:3.62

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.586

ROE:-31.30%

ROA:-10.95%

PB:3.10

PE(LYR):-10.18

PS:263.13

Loading ...

Overview Company News Filings

Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Controlling Shareholder Confidence and New Product Approval

Stock Track | BAO PHARMA-B Soars 5.62% Intraday on Shareholder Confidence, New Product Approval and Buyback Plan

Stock Track | BAO PHARMA-B Soars 6.29% in Intraday Trading on Controlling Shareholder's Share Accumulation Plan and New Product Approval

Stock Track | BAO PHARMA-B Soars 5.56% Intraday on Share Repurchase Approval and Chairman's Planned Purchases

Bao Pharma Reports No Share Capital Changes in April; Confirms Public Float Compliance

Bulletin Express

Stock Track | BAO PHARMA-B Plummets 6.39% Intraday as Market Skepticism Grows Over Buyback and Stake Increase Plans

BAO PHARMA Proposes No 2025 Dividend, Eyes Board Reshuffle and Supervisory Board Abolition Ahead of 26 May AGM

Bulletin Express

Shanghai Bao Pharmaceuticals announces annual shareholder meeting

Stock Track | BAO PHARMA-B Soars 6.67% Intraday on Chairman's Share Purchase Plan and Proposed Buyback Authorization

BAO PHARMA-B (02659) Chairman Dr. Liu Yanjun Plans to Increase Shareholding

Shanghai Bao Pharma says unaware of reasons behind unusual H-share moves

Stock Track | BAO PHARMA-B Plummets 64.33% Intraday as Annual Report Reveals Widening Losses

宝医药-B 2025年业绩：收入显著增长，研发投入持续，财务实力增强

Bulletin Express

BAO PHARMA-B (02659): From Biotech to Foundational Operator in the 18A Sector

BAO PHARMA-B (02659) Gains Acceptance for Recombinant Ulinastatin (BJ044) IND Application, Pioneering New Era in Recombinant Protein Therapeutics

Subcutaneous Administration Breakthrough Arrives as KJ017 Gains Approval, BAO PHARMA-B (02659) Emerges as Hub for Large-Molecule Drugs

Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth

BAO PHARMA-B (02659) Addresses Biopharma Supply Chain Challenges with Technology-Driven Solutions

BUZZ-Shanghai Bao at nearly 4-week high on China regulator nod to new product

Shanghai Bao Secures China Approval for Innovative Subcutaneous Delivery Adjuvant

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02659/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"BAO PHARMA-B","latestPrice":16.14,"timestamp":1788156159480,"preClose":15.82,"halted":0,"volume":460600,"delay":0,"changeRate":0.02022756005056892,"floatShares":153000000,"shares":324000000,"eps":-1.5860820758044916,"marketStatus":"Trading","change":0.32,"latestTime":"08-31 14:02:41","open":15.85,"high":16.49,"low":15.38,"amount":7454716,"amplitude":0.070164,"askPrice":16.15,"askSize":400,"bidPrice":16.05,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.3734561111746948,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788163800000},"marketStatusCode":2,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":15.82,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":3.616489,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":153000000,"roa":"-10.95%","roe":"-31.30%","lyrEps":-1.586082,"volumeRatio":3.616489,"shares":324000000,"dividePrice":0,"high":16.49,"amplitude":0.070164,"preClose":15.82,"low":15.38,"week52Low":15.3,"pbRate":"3.10","psRate":"263.13","week52High":206,"institutionHeld":0,"latestPrice":16.14,"committee":0.428571,"eps":-1.5860820758044916,"divideRate":0,"volume":460600,"delay":0,"ttmEps":-1.3734561111746948,"open":15.85,"prevYearClose":77.55,"prevWeekClose":15.82,"prevMonthClose":17.25,"prevQuarterClose":18,"fiveDayClose":15.73,"twentyDayClose":17.13,"sixtyDayClose":22.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-08-28","current":-11.724854,"percent":0.994253,"low":-150.791275,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"high":-11.128507,"avg":-47.396445,"sd":35.818109,"marketCap":5157026776},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-05","current":-15.389804,"twenty":-78.220574,"median":-65.202887,"eighty":-19.743808,"marketCap":7041199644},{"date":"2026-06-12","current":-13.774642,"twenty":-77.936107,"median":-64.592987,"eighty":-19.178821,"marketCap":6297961903},{"date":"2026-06-18","current":-12.785133,"twenty":-77.726882,"median":-64.454748,"eighty":-18.7468,"marketCap":5857886926},{"date":"2026-06-26","current":-11.736313,"twenty":-77.358698,"median":-62.675612,"eighty":-18.25553,"marketCap":5352615655},{"date":"2026-07-03","current":-13.348826,"twenty":-77.285436,"median":-61.290684,"eighty":-17.828553,"marketCap":6092593580},{"date":"2026-07-10","current":-14.187594,"twenty":-77.122448,"median":-60.663453,"eighty":-17.509903,"marketCap":6467472265},{"date":"2026-07-17","current":-12.348746,"twenty":-76.777398,"median":-59.36056,"eighty":-15.389804,"marketCap":5649258788},{"date":"2026-07-24","current":-12.28898,"twenty":-76.640212,"median":-57.965274,"eighty":-14.102609,"marketCap":5623180271},{"date":"2026-07-31","current":-12.265678,"twenty":-76.228711,"median":-57.553252,"eighty":-13.925373,"marketCap":5623180271},{"date":"2026-08-07","current":-12.759971,"twenty":-76.015489,"median":-56.434485,"eighty":-13.758151,"marketCap":5861146740},{"date":"2026-08-14","current":-11.978357,"twenty":-75.491436,"median":-55.967849,"eighty":-13.50755,"marketCap":5509086758},{"date":"2026-08-21","current":-11.379099,"twenty":-75.31975,"median":-54.455852,"eighty":-13.139203,"marketCap":5245041771},{"date":"2026-08-28","current":-11.185615,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"marketCap":5157026776}],"updateTime":1788142198659},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1177039394","title":"Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Controlling Shareholder Confidence and New Product Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1177039394","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177039394?lang=en_us&edition=fundamental","pubTime":"2026-05-13 10:07","pubTimestamp":1778638055,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.The company's controlling shareholder group,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122118640","title":"Stock Track | BAO PHARMA-B Soars 5.62% Intraday on Shareholder Confidence, New Product Approval and Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1122118640","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122118640?lang=en_us&edition=fundamental","pubTime":"2026-05-11 09:49","pubTimestamp":1778464170,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock surged 5.62% during intraday trading on Monday, significantly outperforming a generally weak biotechnology sector.The rally appears driven by multiple positive company-specific...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160639478","title":"Stock Track | BAO PHARMA-B Soars 6.29% in Intraday Trading on Controlling Shareholder's Share Accumulation Plan and New Product Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1160639478","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160639478?lang=en_us&edition=fundamental","pubTime":"2026-05-08 10:05","pubTimestamp":1778205923,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock price surged 6.29% during intraday trading on Friday, showing significant upward momentum in the market.The rally was primarily driven by two key factors. First, the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198310979","title":"Stock Track | BAO PHARMA-B Soars 5.56% Intraday on Share Repurchase Approval and Chairman's Planned Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=1198310979","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198310979?lang=en_us&edition=fundamental","pubTime":"2026-05-07 10:54","pubTimestamp":1778122483,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock price surged 5.56% during intraday trading on Thursday, reflecting strong positive investor sentiment.The significant movement follows the company's announcement that its share...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131590445","title":"Bao Pharma Reports No Share Capital Changes in April; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1131590445","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131590445?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059385,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 30 April 2026, indicating stable share capital and no equity movements during the month. Authorised...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196495000","title":"Stock Track | BAO PHARMA-B Plummets 6.39% Intraday as Market Skepticism Grows Over Buyback and Stake Increase Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1196495000","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196495000?lang=en_us&edition=fundamental","pubTime":"2026-05-06 10:52","pubTimestamp":1778035975,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock plummeted 6.39% during intraday trading on Wednesday.The decline reflects fading market enthusiasm for the company's previously announced supportive measures. Chairman Liu Yanjun...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114207599","title":"BAO PHARMA Proposes No 2025 Dividend, Eyes Board Reshuffle and Supervisory Board Abolition Ahead of 26 May AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1114207599","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114207599?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:44","pubTimestamp":1777898652,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA) has called its annual general meeting (AGM) for 10:00 a.m. on 26 May 2026 in Shanghai. Shareholders will vote on 13 resolutions covering 2025...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953299","title":"Shanghai Bao Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953299","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953299?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:42","pubTimestamp":1777898534,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals schedules annual general meeting in Shanghai on May 26, 2026.Shareholders will vote on 2025 annual report, final accounts, 2026 budget, board and supervisors’ reports, profit distribution plan, director remuneration for 2026.Resolution seeks reappointment of Ernst & Young as 2026 auditor, with board authorized to set fees up to RMB 2.85 million .Meeting also set to elect executive, non-executive, independent non-executive directors for second board session.Special resolutions include mandates to issue shares, repurchase H shares, abolish board of supervisors, amend articles of association and related policies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLNxXd2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133074617","title":"Stock Track | BAO PHARMA-B Soars 6.67% Intraday on Chairman's Share Purchase Plan and Proposed Buyback Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=1133074617","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133074617?lang=en_us&edition=fundamental","pubTime":"2026-05-04 09:49","pubTimestamp":1777859346,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock price soared 6.67% during intraday trading on Monday, marking a significant rebound for the pharmaceutical company.The surge follows an announcement that Board Chairman and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174280952","title":"BAO PHARMA-B (02659) Chairman Dr. Liu Yanjun Plans to Increase Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=1174280952","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174280952?lang=en_us&edition=fundamental","pubTime":"2026-05-03 19:02","pubTimestamp":1777806140,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) announced that the company has received a notification from its Board Chairman and a member of the controlling shareholder group, Dr. Liu Yanjun. Based on his confidence in the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604711","title":"Shanghai Bao Pharma says unaware of reasons behind unusual H-share moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604711","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632604711?lang=en_us&edition=fundamental","pubTime":"2026-05-03 18:25","pubTimestamp":1777803949,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals issued a clarification on unusual price and trading volume moves in its H shares, stating it was not aware of any reason for the moves, any undisclosed price-sensitive information, or any information needed to avoid a false market.Chairman Liu Yanjun notified board he intends to increase his shareholding via open-market purchases within three months, capped at 38,893,903 H shares to maintain minimum public float compliance.Controlling shareholder group held about 40.57% of issued shares as of announcement date; planned purchases not expected to trigger a mandatory offer under Hong Kong takeover rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260503:nNDL7vKn7k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152362481","title":"Stock Track | BAO PHARMA-B Plummets 64.33% Intraday as Annual Report Reveals Widening Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1152362481","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152362481?lang=en_us&edition=fundamental","pubTime":"2026-04-30 14:30","pubTimestamp":1777530603,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock plummeted 64.33% during intraday trading on Thursday, marking a severe decline for the biotechnology company.The sharp drop followed the release of the company's annual report,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107062675","title":"宝医药-B 2025年业绩：收入显著增长，研发投入持续，财务实力增强","url":"https://stock-news.laohu8.com/highlight/detail?id=1107062675","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107062675?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289425,"startTime":"0","endTime":"0","summary":"上海宝医药股份有限公司（「宝医药-B」或「公司」；股份代号：02659）于2025年在香港联合交易所有限公司主板挂牌上市，并于本年度全面推进合成生物学与重组生物药研发制造。公司年报显示，核心产品的临床进展稳步推进，全年收入大幅提升，同时研发及经营费用投入保持高位，凸显其对拓展创新管线的持续投入。以下为本年度报告的主要内容： 一、公司概况与业务重点...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝医药-B 2025年业绩：收入显著增长，研发投入持续，财务实力增强","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180405523","title":"BAO PHARMA-B (02659): From Biotech to Foundational Operator in the 18A Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1180405523","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180405523?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:02","pubTimestamp":1776909769,"startTime":"0","endTime":"0","summary":"As Hong Kong's 18A biopharmaceutical sector approaches a period of 'value reassessment' in 2026, a profound paradigm shift centered on 'industrialized biomanufacturing' and a 'revolution in drug...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","02659","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102763275","title":"BAO PHARMA-B (02659) Gains Acceptance for Recombinant Ulinastatin (BJ044) IND Application, Pioneering New Era in Recombinant Protein Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1102763275","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102763275?lang=en_us&edition=fundamental","pubTime":"2026-04-17 15:45","pubTimestamp":1776411928,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) recently announced that the Investigational New Drug (IND) application for its self-developed recombinant Ulinastatin (BJ044) has been formally accepted by the National Medical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157440551","title":"Subcutaneous Administration Breakthrough Arrives as KJ017 Gains Approval, BAO PHARMA-B (02659) Emerges as Hub for Large-Molecule Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1157440551","media":"Stock News","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157440551?lang=en_us&edition=fundamental","pubTime":"2026-04-16 13:45","pubTimestamp":1776318311,"startTime":"0","endTime":"0","summary":"After a prolonged period of valuation adjustment and structural reshaping, Hong Kong's 18A biopharmaceutical sector is reaching a critical inflection point, shifting from \"PPT-driven\" narratives to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174331901","title":"Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1174331901","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174331901?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:58","pubTimestamp":1775714297,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.The movement appears...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135451325","title":"BAO PHARMA-B (02659) Addresses Biopharma Supply Chain Challenges with Technology-Driven Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=1135451325","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135451325?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:51","pubTimestamp":1775713881,"startTime":"0","endTime":"0","summary":"While much attention has focused on ADC and bispecific antibody pipelines with strong out-licensing potential, non-oncology pipelines have received less scrutiny. As the oncology field becomes...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625913307","title":"BUZZ-Shanghai Bao at nearly 4-week high on China regulator nod to new product","url":"https://stock-news.laohu8.com/highlight/detail?id=2625913307","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625913307?lang=en_us&edition=fundamental","pubTime":"2026-04-08 15:14","pubTimestamp":1775632473,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Bao at nearly 4-week high on China regulator nod to new product** Shanghai Bao Pharmaceuticals 2659.HK climbs 4.4% to HK$107.3, highest since March 13** Stock set to rise for fifth straight session ** China-based pharma products researcher and developer's product, Human Hyaluronidase for Injection, with project code KJ017, approved for marketing by China's National Medical Products Administration** KJ017 is highly glycosylated recombinant human hyaluronidase used as adjuvant to subcutaneous infusion, including sodium chloride injection, sodium lactate Ringer's injection** YTD, stock up 36.8%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL1N40R07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625994317","title":"Shanghai Bao Secures China Approval for Innovative Subcutaneous Delivery Adjuvant","url":"https://stock-news.laohu8.com/highlight/detail?id=2625994317","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625994317?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:33","pubTimestamp":1775622836,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals  said Chinese regulators approved its KJ017 injection, according to a Hong Kong bourse filing Wednesday.KJ017 is an injectable version of human hyaluronidase designed to administer fluids or drugs subcutaneously, or under the skin, that the firm said is better than animal-derived hyaluronidase products.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":126,"code":"91000000","status":"200"}]}}